672324-91-3

Usage

Uses

Used in Pharmaceutical Research:
4-(5-Oxazolyl)benzylamine is used as a key intermediate for the synthesis of various drugs and bioactive molecules, contributing to the development of new therapeutic agents.
Used in Organic Synthesis:
As a valuable building block, 4-(5-Oxazolyl)benzylamine is used in the synthesis of heterocyclic compounds, which are important in the creation of complex organic molecules with diverse applications.
Used in Agrochemical Production:
4-(5-Oxazolyl)benzylamine serves as a precursor in the production of agrochemicals, playing a role in the development of pesticides and other agricultural chemicals to enhance crop protection and yield.
Used in Materials Science:
4-(5-Oxazolyl)benzylamine is utilized in the field of materials science for the synthesis of new materials with specific properties, such as conductivity, magnetism, or optical characteristics.
Used in Therapeutic Agent Development:
4-(5-Oxazolyl)benzylamine has been studied for its potential biological activities, indicating its use as a therapeutic agent for various diseases, highlighting its multifaceted role in healthcare and medical research.

Upstream product

• 1360616-36-9 tert-butyl 4-(oxazol-5-yl)benzylcarbamate 
• 87150-13-8 4-(oxazol-5-yl)benzonitrile 
• 105-07-7 4-cyanobenzaldehyde 
• 672324-90-2 4-(5-oxazolyl)-benzamide 
• 101752-05-0 methanol hydrochloride 

Downstream Products

• 1415114-74-7 4-methyl-N-(4-(oxazol-5-yl)benzyl)benzenesulfonamide 
• 1415114-09-8 3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenol 
• 1415114-75-8 N-(2,2-dimethoxyethyl)-4-methyl-N-(4-(oxazol-5-yl)benzyl)benzenesulfonamide 
• 1415114-12-3 N-(3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenyl)-1-phenylmethanesulfonamide 
• 1415114-24-7 N-(3-((5-(isoquinolin-6-yl)oxazol-2-yl)amino)phenyl)methanesulfonamide 
• 1422984-95-9 N-(4-(oxazol-5-yl)benzyl)acetamide 
• 1448187-17-4 (2S,4R)-4-hydroxy-1-((S)-2-hydroxypropanoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1448187-15-2 (S)-1-((2S,4R)-4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-yl acetate 
• 1448189-88-5 (2S,4R)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride 
• 1448189-85-2 (2S,4R)-tert-butyl 4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carboxylate 
• 1448186-49-9 C₂₃H₂₄N₄O₄ 
• 1448186-48-8 C₂₂H₂₁N₃O₅ 
• 1448186-47-7 (2S,4R)-1-(3-cyanobenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds Androgen Receptor such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of Androgen Receptor.

BENZOTHIOPHENE DERIVATIVES AS ESTROGEN RECEPTOR INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions?

Modulation of protein-protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose

Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities

E3 ubiquitin ligases are attractive targets in the ubiquitin-proteasome system, however, the development of small-molecule ligands has been rewarded with limited success. The von Hippel-Lindau protein (pVHL) is the substrate recognition subunit of the VHL E3 ligase that targets HIF-1α for degradation. We recently reported inhibitors of the pVHL:HIF-1α interaction, however they exhibited moderate potency. Herein, we report the design and optimization, guided by X-ray crystal structures, of a ligand series with nanomolar binding affinities.

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE

The present invention relates to novel compounds which find utility as modulators, especially inhibitors of VCB E3 Ubiquitin Ligase and as bioactive agents for use as therapeutics for the stimulation of erythropoiesis in a patient or subject including inducement of EPO production in the patient or subject, for the treatment of chronic anemia and ischemia (limits brain injury during episodes of localized anemia, ischemia and/or stroke and damage to cardiovascular tissue during cardiovascular ischemia), as well as enhancing wound healing processes. Pharmaceutical compositions comprising effective amounts of compounds according to the present invention alone or in combination with an additional erythropoieses stimulating agent such as EPO under the tradename procrit or epogen or darbapoietin alfa under the tradename aranesp. Methods of stimulating erythropoiesis in a subject or patient, including increasing the number of red blood cells and/or hematocrit of the patient, treating anemia, including chronic anemia and anemia associated with chronic kidney disease, dialysis, and cancer chemotherapy, ischemia, stroke and damage to cardiovascular tissue during cardiovascular ischemia as well as enhancing wound healing processes and preventing/reducing scarring secondary to healing represent additional aspects of the present invention. Local enhancement of angiogenesis through induction of VEGF including wound healing and reduction of stent occlusion remain additional aspects of the present invention.

Aminooxazole Inhibitors of Cyclin Dependent Kinases

Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, CNS cancer, melanoma, ovarian cancer, and

Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.